Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
Authors
Keywords
Advanced and recurrent endometrial cancer, Cost-effectiveness, Immunotherapy
Journal
GYNECOLOGIC ONCOLOGY
Volume 162, Issue 2, Pages 249-255
Publisher
Elsevier BV
Online
2021-06-06
DOI
10.1016/j.ygyno.2021.05.038
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
- (2021) Chi-leung Chiang et al. JAMA Network Open
- Second-line lenvatinib in patients with recurrent endometrial cancer
- (2020) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
- (2020) Maria Lorenzi et al. Journal of Oncology
- Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
- (2020) Amanda N. Fader et al. CLINICAL CANCER RESEARCH
- Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis
- (2020) Samantha Batman et al. GYNECOLOGIC ONCOLOGY
- Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
- (2020) David S. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost‐Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First‐Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
- (2020) Dong Ding et al. ONCOLOGIST
- Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
- (2020) Tina R. Watson et al. JAMA Network Open
- Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
- (2019) David A. Barrington et al. GYNECOLOGIC ONCOLOGY
- A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
- (2019) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy
- (2019) Emily N. Prendergast et al. GYNECOLOGIC ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer
- (2015) Lindsey E. Minion et al. GYNECOLOGIC ONCOLOGY
- Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
- (2015) Brian M. Slomovitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence on the cost and cost-effectiveness of palliative care: A literature review
- (2013) Samantha Smith et al. PALLIATIVE MEDICINE
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
- (2011) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment
- (2009) Laura J. Havrilesky et al. GYNECOLOGIC ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started